e-Drug3D
1264
TOREMIFENE
INN
TOREMIFENE
cas 89778-26-7
CLASS
ANTINEOPLASTIC
ANTIESTROGENIC
METASTATIC BREAST CANCER
BONE DENSITY CONSERVATION AGENTS
ESTROGEN RECEPTOR ANTAGONIST OR AGONIST
ROUTE (list)
ORAL
ATC code
L02BA02
PK parameters
VD 580 LITER
Cl 5 LITER / HOUR
PPB 99.5 PERCENT
t1/2 120 HOUR
Solubility
0.63 MILLIGRAM / MILLILITER
TARGET ESTROGEN RECEPTOR
PDB
5JQ7 (CRYSTAL STRUCTURE OF EBOLA GLYCOPROTEIN IN COMPLEX WITH TOREMIFENE)
Ligand code = T0R (link to the list of PDB complexes)
Download experimental 3D coordinates of T0R with added hydrogens
Estrogen receptor UNIPROT P03372 ESR1
Formula:
C26H28ClNO
Calculated chemical properties:
MW 405.94
NB_atoms 29
XLogP 6.22
PSA 16.415
NB_HD 0
NB_HA 2
fsp3 0.23
Lipinski(0=no;1=yes) 0
NB_atoms 29
XLogP 6.22
PSA 16.415
NB_HD 0
NB_HA 2
fsp3 0.23
Lipinski(0=no;1=yes) 0
FDA
NDA 020497 (label) INN (TOREMIFENE CITRATE) FARESTON (KYOWA KIRIN) APPROVAL= AP YEAR= 1997 NEWMOLECULARENTITY DISCONTINUED
NDA 208813 (pdf not found) INN (TOREMIFENE CITRATE) TOREMIFENE CITRATE (RISING) APPROVAL= AP YEAR= 2018
NDA 212818 (pdf not found) INN (TOREMIFENE CITRATE) TOREMIFENE CITRATE (MSN) APPROVAL= AP YEAR= 2020
NDA 020497 (label) INN (TOREMIFENE CITRATE) FARESTON (KYOWA KIRIN) APPROVAL= AP YEAR= 1997 NEWMOLECULARENTITY DISCONTINUED
NDA 208813 (pdf not found) INN (TOREMIFENE CITRATE) TOREMIFENE CITRATE (RISING) APPROVAL= AP YEAR= 2018
NDA 212818 (pdf not found) INN (TOREMIFENE CITRATE) TOREMIFENE CITRATE (MSN) APPROVAL= AP YEAR= 2020